April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Pan-retinal, subretinal aggregates in Macular Telangiectasia Type 2
Author Affiliations & Notes
  • Michael B Powner
    Cell Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • Mark C Gillies
    Save Sight Institute, University of Sydney, Sydney, NSW, Australia
  • Meidong Zhu
    Save Sight Institute, University of Sydney, Sydney, NSW, Australia
  • Paul S Bernstein
    Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT
  • Gregory S Hageman
    Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT
  • Catherine A Egan
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Marcus Fruttiger
    Cell Biology, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships Michael Powner, None; Mark Gillies, None; Meidong Zhu, None; Paul Bernstein, None; Gregory Hageman, None; Catherine Egan, None; Marcus Fruttiger, AstraZeneca (F), Novartis (C), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6320. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael B Powner, Mark C Gillies, Meidong Zhu, Paul S Bernstein, Gregory S Hageman, Catherine A Egan, Marcus Fruttiger; Pan-retinal, subretinal aggregates in Macular Telangiectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6320.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Macular Telangiectasia Type 2 (MacTel type 2) is known to affect a specific region in the macula. It is characterised by Muller cell, macular pigment and photoreceptor loss and vascular tortuosity. So far no clinical phenotypes have been described outside this central region. Here we used histopathology to assess whether there are any sub-clinical abnormalities in the peripheral retina in MacTel type 2.

Methods: Post mortem tissue from three MacTel type 2 donors was investigated. Paraformaldehyde tissue was sectioned and immunohistochemistry undertaken looking for photoreceptor, retinal pigment epithelium and glia markers. For ultra-structural analysis paraformaldehyde/glutaraldehyde fixed tissue was osmium tetroxide treated and processed. Semi thin sections were stained with toluidine blue and ultrathin sections were stained with lead citrate for electron microscopy.

Results: Subretinal debris aggregates were found in all three cases of MacTel type 2. In two cases they were found close to the optic nerve head, in the third they were found pan retinal. These debris aggregates included photoreceptor outer segments, containing opsins but not the mitochondrial marker COX2 (inner segment marker). The aggregates also expressed MERTK (but not Stra6 or RPE65) and CRALBP, which co-localised with pigment granules. Localised expression of Vimentin and GFAP was also seen. There was no evidence of increased inflammatory cells in the subretinal space. Semi thin sections reveal subretinal debris aggregates packed with outer segment fragments, but also a pan retinal thin layer of extracellular debris covering the apical surface of the RPE. The RPE have restricted microvilli but otherwise appear healthy. The thin debris layer contains degenerating outer segments and membranous structures.

Conclusions: The clinical phenotype of MacTel type 2 has been well characterised, and to date all evidence suggests a pathology restricted to a specific region in the macula. Our data shows a sub clinical phenotype associated with MacTel type 2 that is pan retinal in the subretinal space. We have not seen any such structures in age matched control tissues.

Keywords: 701 retinal pigment epithelium • 638 pathology: human • 648 photoreceptors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×